NCT02137707View on ClinicalTrials.gov

Biologic Basis for Multiple Sclerosis Disease Progression in RRMS Patients Treated With Gilenya

CompletedOBSERVATIONAL
Enrollment

135

Participants

Timeline

Start Date

November 30, 2012

Primary Completion Date

November 30, 2017

Study Completion Date

October 30, 2018

Conditions
Multiple Sclerosis-Relapsing-Remitting
Interventions
DRUG

Gilenya

All patients will receive Gilenya

Trial Locations (6)

V6T 1Z3

University of British Columbia, Vancouver

Unknown

Dalhousie University Multiple Sclerosis Research Unit, Halifax

Clinique Neuro Rive-Sud, Greenfield Park

Centre hospitalier de l'Universite de Montreal (CHUM), Montreal

K1H 8L6

Ottawa General Hospital, Ottawa

H3A 2B4

Montreal Neurological Institute, Montreal

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

McGill University

OTHER

NCT02137707 - Biologic Basis for Multiple Sclerosis Disease Progression in RRMS Patients Treated With Gilenya | Biotech Hunter | Biotech Hunter